The Impact of Dispensing Business Changes on BD’s Revenue
US dispensing business headwinds BD (BDX) has introduced some changes to its US dispensing business as part of its efforts to transform its medication management solutions. The initiative has impacted the company’s performance due to related accounting changes. For details, read Headwind for Becton Dickinson: US Dispensing Business. These changes had a higher-than-expected impact in 3Q17 and 4Q17, and […]
Johnson & Johnson’s Latest Dividend Payment: Is It Important?
Johnson & Johnson (JNJ) announced a quarterly cash dividend of $0.80 per share on July 18, 2016, payable on September 6, 2016. This is the same as the previous quarter.
How BD Is Accelerating Its Safety Revenues after Flat Growth in 3Q17
Becton Dickinson (BDX), or BD, acquired the global safety products portfolio through the acquisition of CareFusion in 2015.
CalPERS raises position in Staples
Staples began discussions to acquire Office Depot in September 2014. Staples will acquire all outstanding Office Depot shares in the $6.3 billion deal.
What to Expect from St. Jude Medical’s Earnings in 2Q16
In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.
How Long Will Stryker Stock Sustain Its Bullish Trend?
Stryker (SYK) closed at $145.4 on July 18, 2017. It has a 50-day moving average of $141.8 and a 200-day moving average of $132.6.
Farallon Capital adds a new position in Covidien
Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.
Most Analysts Rate Boston Scientific a ‘Buy’
Based on the recommendations of 27 brokerage firms in a Bloomberg survey, about 78% gave Boston Scientific a consensus rating of “buy.”
How Wall Street Reacted to the Delay in BSX’s Lotus Edge Launch
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX’s Lotus devices in Europe and the US on November 28, 2017.
What Does Johnson & Johnson Predict for Its Medical Devices Segment?
Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.
What Analysts Predict for Thermo Fisher’s 2Q17 Revenues
Wall Street estimates that Thermo Fisher Scientific’s (TMO) 2Q17 revenue will come in at ~$4.9 billion, a rise of ~8.5% on a YoY (year-over-year) basis.
Analysts Recommend Boston Scientific as a Strong ‘Buy’
Boston Scientific will release its 1Q16 earnings results on April 27. In a survey of 28 brokerage firms, about 78.6% of the firms rated Boston Scientific as a “buy.”
Dentsply Sirona’s Segments: Q2 2018 Performance
Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%.
Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?
In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.
Could Johnson & Johnson’s Earnings Grow in 3Q16?
Analysts’ estimates Johnson & Johnson (JNJ) accounts for ~6.3% of the total holdings of the iShares Core High Dividend ETF (HDV). The company has managed to exceed analysts’ earnings estimates for the last several quarters. The movement in a company’s share price is generally impacted by the deviation of its actual results from analysts’ estimates. Usually, a stock’s […]
Johnson & Johnson’s 4Q15 Estimates: Revenues Will Fall
On an annual basis, Johnson & Johnson’s revenues have increased over the past few years following the restructuring of its business segments and strong performance of some of its key products.
Trial Progression of St. Jude Medical’s Stroke Prevention Device
On September 1, St. Jude Medical (STJ) launched its AMPLATZER Amulet IDE trial that will expand the device’s access to atrial fibrillation patients.
Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17
Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.
Analyst Recommendations for Stryker: Most Say ‘Buy’
In a Reuters survey of 27 brokerage companies, about 63.0% of analysts have rated Stryker a “buy,” and 26.0% have rated it a “hold.”
What Analysts Are Saying about Becton Dickinson Now
Analysts estimate that Becton Dickinson has a potential to return ~6.4% over the next 12 months. The 12-month target price for BDX is $163.10 per share.
What to Expect from Edwards Lifesciences’ Fiscal 3Q17 Results
Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week high.
Stryker: Analysts’ Recommendations before Its 3Q17 Earnings
Stryker (SYK), the second-largest orthopedic device developer, is set to announce its 3Q17 earnings results on October 26, 2017.
A Look at Abbott Laboratories’ Valuation Multiples
May 3, Abbott Laboratories had a 12-month forward PEG ratio of ~1.5x, compared to the ~1.6x PEG multiple recorded in April.
How Has Medtronic’s Stock Performed Recently?
Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
Johnson & Johnson’s Revenues Continued to Rise in 1Q18
Johnson & Johnson surpassed Wall Street analysts’ estimates for EPS (or earnings-per-share) and revenues in 1Q18.
Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.
Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17
On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.
FDA Approves Medtronic’s Enlite Sensor for iPro2 CGM System
Medtronic (MDT) is consistently working on expanding access to and improving diabetes management via new and enhanced products and services.
Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results
On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
Edwards Lifesciences and Boston Scientific: Patent Dispute Update
Edwards Lifesciences’ and Boston Scientific’s patent dispute On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding […]
JNJ’s Consumer Business Expected to Be Driven by Innovation
Johnson & Johnson started shipments of its revamped baby care line in July, which is expected to register improved performance in the third quarter.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
Antitrust approvals: Assessing the Covidien-Medtronic merger
The Covidien (COV)–Medtronic (MDT) deal is based on complementary products, not necessarily buying out a competitor.
How Much Can Truven’s Data Actually Benefit IBM’s Watson?
IBM intends to strengthen its presence in cognitive computing and machine learning space through Watson, which requires a vast pool of data.
What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.
How Will the Lotus Recall Affect BSX’s 2017 Performance?
Boston Scientific has begun implementing the necessary fixes for its Lotus Valve system, and it expects to relaunch the product in the Europe and other international markets in 4Q17.
How Medtronic’s Cardiac and Vascular Group Performed
Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018.
How Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
What Zimmer Biomet’s Progress II Study Success Could Mean
On December 22, 2017, Zimmer Biomet Holdings (ZBH) published the results of its Progress II trial, and the results were positive.
Diabetes Management Breakthrough: Medtronic’s MiniMed 670G
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
Why Senseonics Holdings Is Up ~5.6% Today
Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then.
Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings
Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.
Analysts’ Views on Tandem Diabetes Care after Its FDA Approval
After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.
Fitbit’s Team Strategy: The Benefits of Acquisitions and Partnerships
In 2016, Fitbit (FIT) inked a deal with Pebble to harvest certain Pebble assets, now that the latter company has begun shutting down operations.
Here’s What Could Boost Medtronic’s Growth in Fiscal 2019
Medtronic’s CSH division’s growth was driven by the constant currency growth of its transcatheter aortic valves.
Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition
On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.
Medtronic’s Key Growth Driver: MiniMed 670G Hybrid Closed Loop
Medtronic’s Diabetes Group performance in fiscal Q4 2018 was driven by a 25% growth for its MiniMed 670G hybrid closed-loop insulin pump.
ABT’s Recent Stock Slump: What’s behind the Decline?
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share.
What’s Intuitive Surgical’s Capital Allocation Strategy?
On December 13, 2016, Intuitive Surgical increased its authorized share repurchase program from $1.0 billion to $3.0 billion.
Johnson & Johnson Accepts Sale of Its LifeScan Business
On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity.
What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?
Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.
ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.
Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.
Medtronic: Wall Street’s Views and Latest Recommendations
On May 31, Medtronic had a consensus 12-month target price of $93.81, implying a 12-month investment return potential of ~9.2%.
How the Freestyle Libre CGM Opportunity Is Playing Out for ABT
Abbott Laboratories stated during its second-quarter earnings release that it’s on track for achieving its fiscal 2018 guidance for Libre.
Analysts’ Recent Recommendations and Target Price for ABT Stock
On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”
Discussing Boston Scientific’s Stock Performance in 2018 So Far
On July 9, Boston Scientific (BSX) stock ended the trading day at $33.79, a rise of ~0.50% compared to the previous day.
Boston Scientific’s Lotus Edge Valve System Gets Approval in Europe
Boston Scientific (BSX) is consistently working towards gaining higher market share in the attractive TAVR (transcatheter aortic valve replacement) market in Europe.
Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?
For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.
Can Intuitive Surgical’s Revenue Grow in 2017?
On July 20, 2017, Intuitive Surgical (ISRG) will announce its 2Q17 earnings. The company has exceeded analysts’ revenue estimates for the last several quarters.
What Triggered a 52-Week High for Boston Scientific in October?
On October 2, Morgan Stanley raised its target price for BSX stock. That day, BSX stock was trading at its 52-week high.
Tandem Diabetes Care’s Stock Performance This Month
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.
Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects
According to Abbott Laboratories, around two-thirds of diabetes patients have Type-1 diabetes while the rest have Type-2 diabetes.
Will Intuitive Surgical Stock Witness Continued Growth Momentum?
Intuitive Surgical (ISRG) has returned approximately 48.2% YTD (year-to-date), surpassing SPY as well as the Health Care Select Sector SPDR Fund (XLV) by enormous margins.
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
Sanofi’s 1Q18: Revenue Expected to Fall
Sanofi’s 1Q18 revenue estimates As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations. Structure of the group The above graph shows Sanofi’s revenue since 1Q17 and estimates for 1Q18. In 2016, Sanofi reorganized its businesses into five units: Sanofi Genzyme, its specialty care business, which […]
Trade War Fears Triggered Medtronic’s Stock Decline on March 23
Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.
Can BAX Stock Maintain Momentum after Recent Highs?
BAX stock plummeted in late 2016 but has witnessed a rise in recent months, trading at a 52-week high on October 27, 2017.
Innovative Products Driving Medtronic’s Growth
Medtronic expects its MITG segment to have an organic growth rate of 4% in fiscal 2019.
How Edwards Lifesciences Trades Compared to Its Peers
As of August 30, 2016, Edwards Lifesciences (EW) was trading at a forward PE (price-to-earnings) multiple of 40x.
St. Jude’s Proclaim Elite SCS System Received CE Mark Approval
On December 8, 2016, St. Jude Medical (STJ) announced CE Mark approval for full body MR (magnetic resonance) conditional labeling for the Proclaim Elite SCS (spinal cord stimulation) System.
How Has Boston Scientific Stock Performed Recently?
Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.
An Investor’s Guide to Top-Performing Stocks for 2020
Overall, tech stocks turned out to be the top performers for 2019. The gain in the technology sector helped the S&P 500 gain 29% in 2019.
Medtronic’s Spine Business Dynamics amid a Challenging Market
In fiscal 2Q18, Medtronic’s Restorative Therapies Group business registered year-over-year sales growth of ~2.0%, which came in below expectations due to the negative impact of Hurricane Maria.
How Johnson & Johnson’s Partnerships Enhance Customer Value
Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.
Guardian Connect Expected to Be Medtronic’s Big Opportunity
On March 12, Medtronic announced that it has received FDA approval for its stand-alone continuous glucose monitoring system Guardian Connect.
Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings
On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.
BD Stock Reaches 52-Week High on November 27
BD released its 4Q17 and fiscal 2017 earnings results on November 2, 2017. That day, the stock rose ~7.7%, registering a record high thanks to the company’s stellar earnings results.
BSX Stock Regains Momentum after Its Recent Bearish Trend
On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.
ZBH Stock Price Momentum Likely to Trend Upward
On January 24, Zimmer Biomet Holdings (ZBH) closed trading at a share price of $125.02. The company traded at a 52-week high of $133.49 on July 17, 2017.
Stryker’s Recent Stock Price Movement: Upside Potential?
Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.
A Look at Medtronic’s Recent Stock Performance
Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.
Abbott Laboratories Continues Its Bull Run with a Record High
On September 26, Abbott Laboratories (ABT) ended the trading day at $72.84, up ~0.89% from the previous day’s close.
Strong TAVR Adoption Is a Key Growth Driver for MDT’s CVG Business
Medtronic’s CVG (Cardiac and Vascular Group) business reported growth of ~7.0% on a YoY (year-over-year) basis.
Must-know: Key export barriers for medical device manufacturers
Most large U.S. manufacturers have invested significant capital into emerging markets, including Medtronics, Johnson & Johnson, GE, and Stryker.
Eli Lilly Rose on FDA’s Approval of Basaglar
Eli Lilly (LLY) gained 0.9% on December 16, 2015. The stock went up on the news that the FDA (US Food and Drug Administration) approved Basaglar.
Boston Scientific Stock in the Week Ended September 14
Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.
Waters Introduces Symphony, Its New Data Pipeline Software
A top IHI performer on June 2, 2016, was Waters (WAT), which rose 0.9%. The company was in the news with the introduction of its new data pipeline software.
IBM Boosted Watson Capabilities through Strategic Acquisitions
IBM (IBM) is betting heavily on Watson, its cognitive computing platform, to steer the company towards much-needed growth.
FDA Approves Boston Scientific’s Emblem MRI S-ICD System
Boston Scientific (BSX) offers a leading portfolio of rhythm management devices around the world.
How Will Abbott Laboratories Benefit from Its Alere Acquisition?
On April 14, 2017, Abbott Laboratories (ABT) agreed to acquire point-of-care diagnostics player Alere (ALR) for an equity value of ~$5.3 billion.
IBM Is Paving the Way for Watson Health: Acquisitions and Deals
IBM’s partnership with Apple is especially appealing. Watson Health will bring cloud services and analytics to Apple’s HealthKit and ResearchKit.
Baxalta Rose on FDA’s Approval of Vonvendi
Baxalta (BXLT) rose by 0.7% on December 9, 2015. The stock moved up as the FDA (US Food and Drug Administration) approved its drug Vonvendi.
Wall Street Maintains ‘Strong Buy’ Recommendation for Stryker
Analysts’ recommendations Stryker (SYK) has registered strong results over the last few quarters and has been expanding at a fast pace through organic and inorganic growth. The company has made a number of acquisitions and expanded its market presence across product lines and regions. Its most recent earnings results were reported on October 26, 2017. For details, read […]
How BD-Bard Acquisition Will Strengthen International Presence
C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.
Abbott’s Freestyle Libre Gets Reimbursement Approval in France
Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.
Understanding Zimmer Biomet’s Latest Dividend Announcement
On December 18, 2017, Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share for fiscal 4Q17.
What to Expect from Medtronic’s Diabetes Segment
In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.